News

Eisai Co., Ltd. announced that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create…
Read More...

Filament Health Corp. a clinical-stage natural psychedelic drug development company, and Psyence Group Inc, a life science biotechnology company pioneering the use of natural psilocybin…
Read More...

Ono Pharmaceutical Co., Ltd. announced that it has entered into a multi target R&D collaboration agreement with PrecisionLife Limited, a global techbio company generating the…
Read More...

Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, announced the…
Read More...

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune,…
Read More...

Harrow, an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, announced that it has entered into…
Read More...

Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that…
Read More...

UCB and Praxis Precision Medicines announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of…
Read More...

Biosion USA, Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the treatment of cancer with ImmunoGen. In the joint research effort,…
Read More...

The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults. Spesolimab is a…
Read More...

Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the…
Read More...

GSK plc and Wave Life Sciences Ltd. a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced a…
Read More...

Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of…
Read More...

Pasithea Therapeutics Corp. a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, announced…
Read More...

Merck, known as MSD outside of the United States and Canada, is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago…
Read More...

CSL Limited announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc (“Arcturus Therapeutics”;…
Read More...

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company…
Read More...

Kite, a Gilead Company and Arcellx, Inc. announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the…
Read More...

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced that Health Canada has approved Empaveli™ (pegcetacoplan), a complement inhibitor, for the…
Read More...

Pfizer Inc. and BioNTech SE announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
Read More...